Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CytomX Therapeutics, Inc. (NASDAQ: CTMX).

Full DD Report for CTMX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTMX)

CytomX to Present at the Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform,...
Source: GlobeNewswire
Date: November, 07 2018 08:00
CytomX misses by $0.09, misses on revenue
CytomX (NASDAQ: CTMX ): Q3 GAAP EPS of -$0.53 misses by $0.09 . Revenue of $12.5M (-48.2% Y/Y) misses by $3.54M . Press Release More news on: CytomX Therapeutics, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 06 2018 16:12
CytomX Therapeutics Announces Third Quarter 2018 Financial Results
ESMO Presentations Support CX-072 Product Profile and Probody™ Proof-of-Concept  Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-2009 and CX-2029  CX-188 IND Filing Marks Fifth Probody Therapeutic to Advance in Clinical Development  Co...
Source: GlobeNewswire
Date: November, 06 2018 16:05
CytomX Therapeutics Announces CX-072 Clinical Presentations at 2018 SITC Annual Meeting
PROCLAIM-CX-072 Clinical Translational Data Presented as Poster and Rapid-Fire Oral Presentation Company to Host Analyst and Investor Event and Webcast SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) a clinical-stage oncology-...
Source: GlobeNewswire
Date: November, 06 2018 08:12
CytomX Therapeutics to Announce Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform,...
Source: GlobeNewswire
Date: October, 30 2018 16:03
CytomX Therapeutics (CTMX) Presents at 2018 Wedbush PacGrow Healthcare Conference - Slideshow
The following slide deck was published by CytomX Therapeutics in conjunction with this Read more ...
Source: SeekingAlpha
Date: August, 15 2018 14:39
CytomX misses by $0.03, beats on revenue
CytomX (NASDAQ: CTMX ): Q2 EPS of -$0.35 misses by $0.03 . More news on: CytomX Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:16
CytomX Therapeutics Announces Second Quarter 2018 Financial Results
- Presentation of First-in-Human Data Demonstrated Encouraging Safety and Efficacy Profile of CX-072 as Monotherapy and in Combination with ipilimumab (Yervoy®) - - Preliminary Proof-of-Concept for Probody™ Platform and CX-072 - ...
Source: GlobeNewswire
Date: August, 08 2018 16:04
CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform,...
Source: GlobeNewswire
Date: August, 07 2018 16:01
Report: Developing Opportunities within OMNOVA Solutions, Natural Health Trends, Vocera Communications, Oppenheimer, CytomX Therapeutics, and The Ultimate Software Group - Future Expectations, Projections Moving into 2018
NEW YORK, Aug. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OMNOVA Solutions Inc. (NYSE:OMN), Natural Health Trends Corp. (NASDAQ:NHT...
Source: GlobeNewswire
Date: August, 03 2018 07:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0820.1320.1420.2819.70338,960
2018-08-3122.3822.4922.6721.76579,421
2018-08-3023.1922.7224.2022.63323,894
2018-08-2924.0623.3124.3423.19463,079
2018-08-2823.9524.0724.32523.58167,783

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1139,65468,19058.1522Short
2018-12-1020,57235,79857.4669Short
2018-12-0733,00249,57766.5672Short
2018-12-0623,03839,03259.0234Short
2018-12-0467,03998,21068.2609Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTMX.


About CytomX Therapeutics, Inc. (NASDAQ: CTMX)

Logo for CytomX Therapeutics, Inc. (NASDAQ: CTMX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $897,323,312 - 05/15/2018
  • Issue and Outstanding: 38,611,158 - 03/05/2018

 


Recent Filings from (NASDAQ: CTMX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: March, 14 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: CTMX)

Daily Technical Chart for (NASDAQ: CTMX)


Stay tuned for daily updates and more on (NASDAQ: CTMX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTMX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CTMX and does not buy, sell, or trade any shares of CTMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/